A Study to Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.
← catalyst calendarSponsored by Pfizer (industry) · PFE — their whole pipeline →. With Hoffmann-La Roche.
Phase
Phase 1/2
Status
Terminated
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
40actual
Sites
10
Countries
Israel, Japan, Turkey (Türkiye) +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
Business/Administrative decision to pursue other programs/assets within the oncology portfolio. Not due to any detected safety signals or requests from regulatory authorities.
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-08-30 | actual | When the study began enrolling |
| Primary completion | 2026-04-09 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-04-09 | actual | The whole study's end, after follow-up |
| First posted | 2023-06-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Diffuse Large B-Cell Lymphoma
Interventions
- Drug: maplirpacept (PF-07901801)
- Drug: Glofitamab — also filed as Columvi
- Drug: Obinutuzumab — also filed as Gazyva
Primary outcomes
what the primary-completion date above is the date OFPhase 1b: Number of participants with Dose limiting toxicities (DLT)
measured 21 days following first PF-07901801 dose
Phase 2: Objective Response (OR)
measured Time from the date of first dose of study intervention until the first documentation of disease progression, death, or start of new anticancer therapy (assessed up to approximately 24 months)
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed